DJIA 17,730.11 -27.80 -0.16%
NASDAQ 5,009.21 0.00 0.00%
S&P 500 2,076.78 -0.64 -0.03%
market minute promo

Peregrine Pharmaceuticals (NASDAQ: PPHM)

1.30 0.01 (0.78%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

PPHM $1.30 0.78%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.30
Previous Close $1.29
Daily Range $1.29 - $1.31
52-Week Range $1.19 - $1.89
Market Cap $244.8M
P/E Ratio -4.48
Dividend (Yield) $0.00 (0.0%)
Volume 543,715
Average Daily Volume 1,318,447
Current FY EPS -$0.30

Sector

Healthcare

Industry

Drug Makers

Peregrine Pharmaceuticals (PPHM) Description

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases. Website: http://www.peregrineinc.com/

News & Commentary

Small Cap Stocks to Watch in Biotech

Small cap stocks can be some of the most intriguing buys for investors. Here are three from the biotech sector that you may want to add to your watchlist.

Peregrine Pharmaceuticals Granted Key European Patent for Its Lead Clinical Drug Candidate Bavituxim

Peregrine Pharmaceuticals Granted Key European Patent for Its Lead Clinical Drug Candidate Bavituximab

1 Drug Will Make or Break These 3 Biotech Stocks

Our experts weigh in.

Peregrine Pharmaceuticals (PPHM) Weak On High Volume Today

Peregrine Pharmaceuticals, Inc. (PPHM) in Focus: Stock Jumps 5.2% - Tale of the Tape

Data Presentations at ASCO Demonstrate the Ability of Peregrine Pharmaceuticals' Bavituximab to Acti

Data Presentations at ASCO Demonstrate the Ability of Peregrine Pharmaceuticals' Bavituximab to Activate Tumor Targeting Immune Cells in PD-L1 Negative NSCLC Tumors

Peregrine Pharma Announces Presentations at ASCO Showed Ability of Bavituximab to Activate Tumor Tar

Peregrine Pharma Announces Presentations at ASCO Showed Ability of Bavituximab to Activate Tumor Target Immune Cells in PD-L1 Negative NSCLC Tumors

A Tax Advantaged 11.4% Yield From Peregrine Pharmaceuticals Preferred Stock

Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2015 Annual Me

Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2015 Annual Meeting

5 Promising Biotech Stocks Under $10

Don't let their share price fool you. These five biotech stocks have the potential to double your money many times over if their product pipelines meet expectations.

See More PPHM News...

PPHM's Top Competitors

PPHM $1.30 (0.78%)
Current stock: PPHM
AMGN $153.26 (-1.12%)
Current stock: AMGN
BIIB $404.28 (-0.28%)
Current stock: BIIB
CELG $119.52 (1.10%)
Current stock: CELG